Novacyt and Lab21 Announce stock for stock Completion

Novacyt (NYSE-ALTERNEXT: ALNOV), a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers, and Lab21, the Cambridge, UK-based global specialist in personalised medicine and clinical diagnostics, have completed their stock for stock transaction announced on 27 May, 2014. Download press

Visit Page